diksha3847's blog

Market Insights

Autoimmune diseases are on the rise, and chronic inflammatory demyelinating polyneuropathy (CIDP) is no exception. Although CIDP is a rare disease, it has been growing in prevalence. Chronic inflammatory demyelinating polyneuropathy is a rare autoimmune disorder wherein the body's immune system attacks the myelin causing various symptoms such as numbness, weakness, and a lack of certain reflexes. Market Research Future has dedicated studied the market to its full extent for the forecast period between 2018 and 2023. In 2017, the market was observed to have reached a market value of USD 2723.42 Mn. MRFR ascertains that the global chronic inflammatory demyelinating polyneuropathy market is due to register growth at a CAGR of 6.2%. This projection is likely to lead the market toward an upward trend and result in a market value of USD 3907.17 Mn by the end of the assessment period in 2023.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6947

Autoimmune diseases have been witnessed to be increasing in prevalence. According to the American Autoimmune Related Diseases Association, nearly 50 Mn Americas were recorded to have been suffering from autoimmune diseases in 2017. The cause of chronic inflammatory demyelinating polyneuropathy has not yet been identified and can occur in any individual regardless of genetic makeup. This has directly resulted in an increase in research and development with regards to treatment. For the chronic inflammatory demyelinating polyneuropathy market, growth is expected to induced by the increasing R&D related to plasma-derived medicines. Most recently in 2017, this resulted in the FDA approval of a new immune globulin intravenous treatment of CIDP called Privigen. Moreover, the market is being supported by the increasing awareness regarding chronic inflammatory demyelinating polyneuropathy (CIDP). Increasing incidences of this diseases combined with government intervention to provide support to patients suffering from chronic inflammatory demyelinating polyneuropathy will drive market growth. Favorable reimbursement policies and involvements of non-profit organizations are among the various factors driving the market's growth.

The Chronic Inflammatory Demyelinating Polyneuropathy Market Size faces a few challenges with regards to the high cost of intravenous immunoglobin (IVIG) treatment as well as the various side effects associated with IVIG treatment. Common side effects include migraines, mild fever, myalgia, and several others. However, due to the consistent R&D activities taking place, the market is likely to witness opportunities in the form of advancements in CIDP treatments. The growing prevalence of the disease has created a strong demand for effective medication and treatment options which display high opportunity potential for market players.

Key Players

MRFR's study of the global chronic inflammatory demyelinating polyneuropathy includes identification and analysis of the various market participants competing in the global market. Prominent competitors include Kedrion S.p.A, Octapharma, CSL Behring, Pfizer, Inc, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Baxter, Bio Products Laboratory Ltd., Grifols, and Teijin Pharma Limited.

Market Segmentation

The market structure which has been determined by various components in MRFR's report has been segmented on the basis of treatment & diagnosis, route of administration, end-user, and region. Treatment and diagnosis of chronic inflammatory demyelinating polyneuropathy have been segmented into treatment and diagnosis. The treatment segment which holds the most significant share of the market is sub-segmented into corticosteroids, intravenous immunoglobin (IVIG), plasmapheresis (plasma exchange), physiotherapy, and others. The treatment segment is also growing at the highest CAGR of 6.32% during the review period due to rising demand for effective treatments for CIDP. Among the various sub-segments, the IVIG sub-segment has achieved a leadership status due to the preference for IVIG as the first line of treatment for CIDP.

Route of administration of chronic inflammatory demyelinating polyneuropathy medication has been segmented into oral, intravenous, and others. Due to the high preference for IVIG treatment which enters the bloodstream directly to react faster, the intravenous segment by route of administration has both acquired the largest share of the market and is growing at the highest CAGR during the forecast period. The intravenous segment accounts for 85% of the total market share, followed by oral and others.

End-users in the chronic inflammatory demyelinating polyneuropathy market have been segmented into specialty neurological clinics, hospitals, research & academic laboratories, and others. Hospitals have amassed a 49% share of the global market due to their widespread presence and the preference for hospitals among patients. However, patients are increasingly seeing the value in specialty clinics where they may understand their illness better. As a result, the specialty neurological clinics segment is growing at the most rapid CAGR of 6.49% during the review period.

Regional Analysis

The main geographies covered in MRFR's report include the Americas, Europe, Asia Pacific, and the Middle East & Africa. The global chronic inflammatory demyelinating polyneuropathy market has witnessed the highest presence in the Americas market. Possessing a share of 52% of the global market, the Americas have a leadership position in the market due to the presence of a significant pool of patients suffering from CIDP. Moreover, the strong presence of several leading players in the market is expected to reveal opportunities for growth. The chronic inflammatory demyelinating polyneuropathy disorder is highly difficult to diagnose as its symptoms can often be mistaken for other diseases or disorders. The Americas developed countries have a highly advanced healthcare system which makes the diagnosis of chronic inflammatory demyelinating polyneuropathy easier, thus supporting the regions market position.

Meanwhile, the Asia Pacific is being projected as the fastest growing regional chronic inflammatory demyelinating polyneuropathy market at a CAGR of 7.03% during the review period. The region has an increased availability of funds for research and development activities due to a growing focus on healthcare and healthcare reform. Moreover, the presence of significant expertise in the region is likely to encourage market growth in the coming years.

Notably, the Middle East and Africa market is also expected to grow at a significant pace due to the presence of emerging economies where the healthcare sector is developing swiftly. Middle Eastern countries, in particular, are anticipated to drive market growth.

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/chronic-inflammatory-demyelinating-polyneuropathy-market-6947

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Biologics Market Overview:

Biologics, also known as biopharmaceuticals, are medicines that are extracted or semi-synthesized using biological sources including body cells of human, animals, and microorganisms through biotechnology. Biologics can be composed of proteins, sugars, and nucleic acids or complex combinations of these substances, living cells or tissues.

Completely different from synthesized pharmaceuticals, Biologics refers to a range of medicinal products including vaccines, blood components, somatic cells, tissues, a recombinant therapeutic protein, and living cells. Drugs produced using biologics are used in the treatment of an array of chronic diseases.

Owing to the burgeoning healthcare sector that is proliferating vigorously over the past decades, the biologics market is too growing rapidly. The rising regulatory convergence and better access to healthcare led by improving economic conditions worldwide are key driving forces behind the market growth. Moreover, the huge demand for biologics in the production of pharmaceuticals and vaccines is escalating the market on the global platform.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/1339

Considering the exponential traction, the biologics Market Size perceives currently, Market Research Future (MRFR) in its recently published study report asserts that the global biologics market will reach a valuation of USD 285,520.4 MN by 2023, registering a CAGR over 6.95% throughout the forecast period (2018-2023).

Additional factors supporting the market to grow rapidly, include the growing incidences of chronic diseases and their diagnoses across the globe, increased availability of advanced diagnostic procedures, rising government initiatives in healthcare, and the growing technological advancements in research. Also factors such as the expansion of key producers and the investments they made in R&D for the incremental innovation and to sustain competition foster the market growth to an extent.

On the other hand, factors such as the challenges occurred during the manufacturing of biologics are expected to impede the market growth over the forecast period. Nevertheless, factors such as the increasing awareness for technologically advanced medical procedures and drugs and higher spending power are expected to support the market growth throughout the assessment period.

Major Players:

Key players leading the global biologics market include Pfizer Inc. (U.S.), AbbVie, Inc. (U.S.), AstraZeneca (U.K.), F. Hoffman-La Roche AG (Switzerland), Novartis AG (Switzerland), Bayer AG (Germany), Sanofi (France), Amgen (U.S.), Eli Lilly and Company (U.S.), and GlaxoSmithKline Plc (U.K.) among others.

Global   Biologics   Market   –   Segments

For enhanced understanding, the report has been segmented into four key dynamics.

By Product: Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, and Gene Therapy among others.

By Disease Indication: Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, and Diabetes among others.

By Manufacturing: In-house and Outsourced

By Regions: Asia Pacific, North America, Europe, and the Rest-of-the-World.

Global Biologics   Market   –   Regional Analysis

The North American region, heading with its well-developed healthcare sector accounts for the leading position in the global biologics market followed by the European and Asia Pacific region, respectively.  Simultaneously, factors such as the high-volume production of pharmaceuticals and the huge demand for biologics led by the high healthcare expenditure.

Undoubtedly, the availability and the wide uptake of new technologies to develop advanced production methods is positively impacting market growth. The US, backed by the huge technological advancements in the field of manufacturing biologics leads the regional market.

Get Full Report at https://www.marketresearchfuture.com/reports/biologics-market-1339

The European region owns the next largest share in the global biologics market, following the North American market closely.  Factors propelling the growth of the regional market include the resurging economy that is availing the best possible healthcare & substantially high healthcare expenditures and the government support that encourages manufacturers of biologics to develop new and effective biologics.

The Asia Pacific region is emerging as a profitable market for biologics due to the rapidly improving healthcare infrastructure. Moreover, factors such as the ever-increasing population that is continually dictating the demand for quality healthcare and the spreading awareness towards the availability and benefits of biologics are positively impacting the growth in the regional market.

Rapidly developing economies are expected to provide immense opportunities for the growth of biologics. Also, the increasing adoption of technologies is positively impacting market growth in the region. Furthermore, rising healthcare concerns along with the fast-proliferating healthcare sector, increase the market size of the biologics market in the APAC.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Market Highlights

The Global Blood Screening Market Report is expected to register a growth of significant CAGR 9.8% during the forecast period (2018–2023).

Blood screening is a medical process in which the blood is examined for the diagnosis of a specific diseased condition is known as blood screening. Exhaustive screening is essential for all donated blood to confirm that recipients receive the safest products. Scientific advances increase the sensitivity and effectiveness of the tests. For example, in August 2016, the Food and Drug Administration (FDA) suggested the testing of all the donated blood in the U.S. and its territories for Zika virus in order to prevent transmission of this virus through the blood supply. The technology is cheaper and faster than earlier DNA analysis methods. The growth of the market is credited to the rise in demand for blood screening tests due to growing blood donations, increasing awareness about transfusion-transmitted diseases, and technological developments in the industry. Additionally, governments of various countries are in process to mandates testing all donated blood for several viruses.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6899

Key Players:

Some of the key players in the global blood screening market Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary of Danaher Corporation) and Becton, Dickinson and Company

Segmentation:

The global blood screening market has been segmented on the devices, service providers, application, end users.

On the basis of technology, the market has been classified as nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, next-generation sequencing (NGS), western blotting. The nucleic acid amplification test is segmented in to transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). The enzyme-linked immunosorbent assay is segmented in to ELISA market, by platform and ELISA market, by generation. On the basis of products and services, the market has been classified as reagent and kits, enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides, and solutions, immunosorbents, instruments and software and services. The reagent and kits have been segmented in to NAT reagents & kits, ELISA reagents & kits. The instruments have been segmented in to rental purchase and outright purchase. On the basis of end users, the market has been classified as hospitals, clinics, research institutes and academic centers, blood banks and others.

Regional Analysis:

The Americas is projected to lead the blood screening market in the forecast period. Increasing healthcare awareness, advancement in technology, medical tourism are some other factors that boost the growth of the market. U.S. blood screening market dominated industry in 2017, due to the high demand for quality healthcare, vastly developed healthcare infrastructure as well as growing occurrence of cardiac disease in the region. Frequencies of blood screening are dramatically increasing over the last few years. Lately, the Food and Drug Administration (FDA) published a guidance document suggesting regulations for laboratory developed tests. In addition, In February 2015, the U.S. FDA conducted a workshop to discuss the oversight of NGS. All these factors increase awareness, which would further increase the growth of the industry.

The European market is expected to hold the second largest market share. The market is expected to witness growth owing to the rising patient population, changing lifestyle, and growing elderly population. This is expected to provide favorable backgrounds for the market to grow.

Asia-Pacific is projected to be the fastest growing region for the global blood screening market in 2018. It is expected to witness profitable growth over the forecast period due to the existence of favorable healthcare schemes drafted by government agencies Other factors such as growing elderly population, rising demand for advanced and high-end technologies, healthcare reforms for infrastructural development and growing healthcare expenditure are some of the key factors that will accelerate the blood screening market growth during the forecast period.

The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/blood-screening-market-6899

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Key Players:

Some of the key players in the Global Traumatic brain injuries treatment market  are Neuren Pharmaceuticals Ltd., Oxygen Biotherapeutics Inc, Ischemic,  Grace Laboratories LLC. Cognosci, Medicortex, Amarantus BioScience Holdings, Aldagen, TEVA Pharmaceutical Industries Ltd., NeuroScience Pharmaceuticals, Targacept, BioDirection, Inc., QuesGen Systems, Inc., BrainScope Company, Inc., Oculogica, BrainScope Company, Inc, Vasopharm GmbH, Silver Creek Pharmaceuticals Inc, Stemedica Cell Technologies Inc, Neural Analytics Inc, Banayan Biomarkers Inc, Zimmer Biomet.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6839

Market Highlights:

Traumatic brain injury (TBI) occurs from a violent blow or head injury that disturb the normal functioning of the brain. Every year TBI contributes to a substantial number of death and permanent disability. Elder age population holds the largest share of Traumatic Brain Injuries Treatment Market Report due to increasing incidence of road accident and high rate of hospitalization and is expected to grow staidly during the forecast period. Whereas on the basis of treatment, medication (drug) segment holds the highest share of this market. Increasing incidences of road traffic injury and the government initiatives to fund for traumatic brain injuries project will boost the traumatic brain injuries treatment market during assessment period.

However, high cost of treatment and devices may hamper the growth of global traumatic brain injuries treatment market during the forecast period.

The global traumatic brain injuries treatment market is dominated by many market players. The key players in the market are engaged in new launches of drug and devices so as to maintain the strategic collaborations to hold its market position. Recently the US FDA has approved the blood test to diagnose the traumatic brain injury.

Segmentation:

Global traumatic brain injuries treatment market is further segmented into treatment types and end-users.

Based on treatment types the market is segmented into immediate emergency care, medications, surgery. On basis of medication global traumatic brain injuries treatment market is further sub-segmented into diuretics, anti-seizure drugs, coma-inducing drugs, anti-anxiety agent, anti-depressants, anti-psychotics, analgesic, anti-convulsant and anti-coagulants.

Based on surgery, TBI market is further sub-segmented into removing clotted blood (hematomas), repairing skull fractures, bleeding in the brain, opening a window in the skull, rehabilitation.

On basis of end-users global TBI market is further segmented into hospitals, neurologist, rehabilitative center treatment, independent pharmacies and others.

Regional Analysis:

The market in the Americas is expected to dominate the global traumatic brain injuries treatment market during the forecast period owing to the increasing incidences of road traffic injuries and increasing hospitalization of geriatric population due to TBI. Additionally, the growing incidences of road traffic collision associated with the aging population are anticipated to boost the growth of the market in this region. Whereas North America holds the highest share of global traumatic brain injury treatment due to increasing number of TBI patients and increasing investment by government in research and development activity on diagnosis management. The European market is expected to be the second-largest due to government funding and support of the healthcare sector coupled with the growing incidence of elderly patients, increasing incidences of road traffic collision and funding by the government for traumatic brain injury project. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to growing number of neurological centers and increasing incidences of road accident. The market in the Middle East & Africa is likely to account for the smallest share of this market. The market growth in this region can be attributed to increasing healthcare expenditure and developing healthcare infrastructure.

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/traumatic-brain-injuries-treatment-market-6839

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Segmentation:

The global renal denervation market is segmented on the basis of product, technology, and end use.

By product, the renal denervation market is segmented into Symplicity, Vessix (V2), EnligHTN, Paradise, Iberis, and others. Symplicity holds the largest market share in the renal denervation market at present and is likely to remain a leading contributor over the forecast period. However, Paradise is likely to be the fastest growing product segment in the renal denervation market over the forecast period.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6712

On the basis of technology, the Renal Denervation Market Size is divided into radiofrequency, ultrasound, micro-infusion, and others. Radiofrequency is likely to be the fastest growing segment over the forecast period, eclipsing ultrasound, the largest market segment at present, in terms of growth rate.

By end user, the renal denervation market is segmented into hospitals, clinics, ambulatory surgical centers, and others. Hospitals are the largest segment in the global renal denervation market, while ambulatory surgical centers are expected to exhibit the fastest growth over the forecast period

Renal Denervation Market Overview:

The Global Renal Denervation Market is expected to rise at a solid CAGR of 40.4% over the 2018-2023 forecast period, according to a new research report from Market Research Future (MRFR). The market’s value is expected to rise from USD 200 million in 2017 to USD 2,850 million in 2023.

The global renal denervation market is expected to be driven mainly by the rising prevalence of hypertension around the world. Hypertension has been one of the main beneficiaries of the modern lifestyles and dietary patterns, and has grown in prevalence steadily over the last decade and more. This trend is likely to be followed over the coming years as more countries experience the negative effects of rapid urbanization and wide-scale industrialization on the health of the population. Hypertension is likely to be one of the diseases on the rise in developing countries that are pursuing large-scale urbanization and industrialization, leading to favorable growth prospects for the renal denervation market in emerging economies such as China and India.

Competitive Analysis:

Leading players in the global renal denervation market include Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiosonic, Cordis, Kona Medical, Sound Intervention, and Terumo.

Regional Analysis:

By region, the global renal denervation market is segmented into North America, Europe, Asia Pacific (APAC), and Rest of the world.

Europe is likely to dominate the global renal denervation market over the forecast period due to the strong research infrastructure in the region and the increasing development of progressively more advanced renal denervation devices. The increasing prevalence of drug-resistant hypertension in Europe is further likely to drive research in the renal denervation market, ensuring Europe’s dominance in the renal denervation market over the forecast period.

Asia Pacific is also likely to be a major regional market for renal denervation over the forecast period due to the growing prevalence of hypertension and the steady improvement in healthcare infrastructure. This is likely to ensure widespread availability of renal denervation devices as well as increasing research into product development to produce more advanced renal denervation devices over the forecast period.

The renal denervation market is hamstrung by challenging government regulations in regions such as the U.S. Medtronic recently announced the launch of a new placebo-controlled randomized clinical trial in an effort to get regulatory approval in the U.S., a major commercial market for high blood pressure remedies.

Get Full Report at https://www.marketresearchfuture.com/reports/renal-denervation-market-6712

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Urgent Care Apps Market Overview:

The Global Urgent Care Apps Market continues on a gradual upward trajectory and is expected to cross USD 2595 Mn mark by the end of 2023. The global urgent care apps market stood at USD 314.2 Mn in 2017 and Market Research Future (MRFR) anticipates dynamite growth in the market with a CAGR over 42.20% over the forecast period which ends in 2023.

Urgent care apps are advantageous in managing medical conditions which need immediate attention. They act as an additional pathway for medical conditions which require prompt action but are non-life-threatening concerns. They offer an effective and low-cost option for the management of health conditions such as pregnancy, stroke, cardiac diseases, trauma, and others. Multiple use cases presented by urgent care apps are boosting the growth of the market. Also, these apps have been proven beneficial in post-hospital or post-operative care among patients.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6677

The ubiquity of smartphones coupled with the growing penetration of 3G and 4G networks, especially in the emerging economies are contemplated to be reflecting positively on the growth of the global urgent care apps market. The digital revolution in healthcare is speeding up the adoption of urgent care apps and consequently fostering market growth.

The gradual shift in focus on personalized and patient-centric healthcare delivery has been a key driver for the growth of the global urgent care apps market. Urgent care apps deliver a diverse set of services with more flexible hours. They are particularly useful for elderly patients who require reassurance and offer them with access to immediate help during emergencies. 

Raising awareness regarding the availability of medication management apps in combination with the factors mentioned above add fuel to the growth of the global urgent care apps market.

However, the market might be met by some challenges including the bulk of miscategorized apps in the App Store & Google Play and poor internet connectivity issues in underdeveloped regions which restrict the growth of the market.

Competitive Landscape

Some of the prominent players operating in the global urgent care apps market include Forward Health, Pivot Design Group, Johnson & Johnson, Twiage, Siilo, Alayacare, PatientSafe Solutions, Vocera Communications, Hospify, Argusoft, Voalte, Pulsara, Imprivata, Allm, and TigerConnect.

Segmentation

The Global Urgent Care Apps Market Size has been segmented based on type and clinical area.

By type, the urgent care apps market has been segmented into emergency care triage apps, in-hospital communication & collaboration apps, and post-hospital apps. The post-hospital apps segment has been further segmented into medication management apps, care provider communication & collaboration apps, and rehabilitation apps.

By clinical area, the global urgent care apps market has been segmented into trauma, stroke, cardiac conditions, and others. The trauma segment is the largest segment on account of rising incidences of road accidents which necessitates trauma care and increasing awareness to address trauma by healthcare organizations. The cardiac conditions segment is expected to be the fastest growing segment owing to the gradual realization of the benefits of urgent care apps in the management of critical cardiac conditions.

Regional Analysis

The Americas, Europe, Asia Pacific, and the Middle East & Africa are the key markets for urgent care apps.

North America is a significant market for urgent care apps, led by North America. Deep penetration of smartphones and 3G and 4G networks along with escalating healthcare cost and constant need to address the same are augmenting the market in North America. Moreover, the region tends to quickly adapt to emerging technologies which further supports the growth of the urgent care apps market. Other driving factors include raising awareness and increasing focus on personalized healthcare.

Europe's market growth can be exclusively attributed to increasing initiatives by the government towards the promotion of such apps and towering need to curtail healthcare costs. Germany, Italy, France, Spain, and the UK are the major markets in Europe.

Asia Pacific market for urgent care apps is anticipated to have an expeditious growth in the coming years. Growing penetration of smartphones in the emerging economies of Asia Pacific coupled with raising awareness about healthcare management apps can be accredited for the growth of the urgent care apps market in Asia Pacific.

Access Report Details @ https://www.marketresearchfuture.com/reports/urgent-care-apps-market-6677

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Adrenocortical Carcinoma Treatment Market Overview:

Market Research Future (MRFR) announces the publication of its research report –Global Adrenocortical Carcinoma Treatment Market, 2018–2023. It is estimated that the global adrenocortical carcinoma treatment market is expected to grow at a CAGR ~ 2.6 % with a projected market value of 678 million during the forecast period of 2018–2023.

Get Sample Report at https://www.marketresearchfuture.com/sample_request/6567

Adrenocortical carcinoma (ACC) is a rare and highly aggressive carcinoma. According to the US National Library of Medicine, the overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 months. The rising incidence rate, a rise in the number of drugs in clinical trials for specific chemotherapeutics, and the increase in risk-factors are anticipated to drive the growth of the market during the assessment period. According to the International Pediatric Adrenocortical Tumor Registry, the female-to-male ratio for adrenocortical carcinoma is approximately 2.5-3:1. Inherited disorders such as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked with increased incidences of adrenocortical carcinoma. According to the survey by Endocrine Society, 2014, adrenocortical carcinoma comprises an approximate 3% to 10% of malignancies in LFS and over 5-15% of malignancies in BWS.  However, differentiation of benign and malignant tumor in the initial stages needs proper evaluation. The pathohistological diagnosis also remains challenging.  These factors coupled with the lack of oncology experts may restrain the growth of the market during the forecast period.

Key Players:

Some of the key players in the global Adrenocortical Carcinoma Treatment Market Size are Pfizer Ltd., Arqule, EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO. ,Ltd., Hitachi, Ltd., NeuroLogica Corp., and Digirad Corporation.

Segmentation:

The global Adrenocortical Carcinoma Treatment Market Analysis has been segmented into type, therapy, and end-user.

Currently, the global adrenocortical carcinoma treatment market is dominated by several players. The prominent players in this market are involved in new product launches, strategic partnerships to expand their product portfolio.  For instance, in April 2015, ArQule, Inc. announced ARQ 087 is currently in a Phase 2 trial in patients with Intrahepatic Cholangiocarcinoma (ICC) with FGFR2 fusions and a Phase 1b trial in adrenocortical tumors and tumors with FGFR translocations, amplification, and mutations. ARQ 087 is a potent FGFR (Fibroblast Growth Factor Receptor) inhibitor. Also, in March 2018, the University of Colorado Anschutz Medical Campus presented novel models to recognize genetic targets and test promising treatments in adrenocortical carcinoma at the ENDO Conference exploring a new therapeutic option.

Regional Analysis:

On a regional basis, the adrenocortical carcinoma treatment market in the Americas is anticipated to dominate the market during the forecast period. The market growth in this region is owing to the advanced healthcare expenditure and advancements in medical device technologies. Moreover, higher demand for quality products and the availability of reimbursement policies are expected to contribute to the market growth in this region.

Access Report @ https://www.marketresearchfuture.com/reports/adrenocortical-carcinoma-treatment-market-6567

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Pharmaceutical Waste Management Market Overview:

Pharmaceutical waste is a concern for all types of healthcare facilities and is generated from pharmaceutical developers and manufacturers, hospitals, individual physicians and from all those who are involved in the healthcare system. Pharmaceutical wastes are hazardous and form a cause for apprehension since they pose a severe threat to human, animal, and environmental health. Pharmaceutical waste management market is expanding at a healthy pace as pharmaceutical waste disposal is gaining more attention from the healthcare sector as well as the consumers. Market Research Future (MRFR) projects steady growth in the global pharmaceutical waste management market over the forthcoming years. Pharmaceutical wastes contain active ingredients which are known to cause harm to the environment and public health. Various human and veterinary pharmaceutical compounds have been found in drinking water resources in concentration which has directed the focus of concerned authorities towards proper disposal of pharmaceutical waste. Pharmaceuticals have not only been found in water but also on the ground surface.  Educating consumers and healthcare professionals about appropriate pharmaceutical waste disposal can make a significant impact on public health and the environment owing to which healthcare professionals and pharmacists are initiating towards imparting knowledge about the consequences of improper pharmaceutical waste disposal. The pharmaceutical industry is one of the most profitable and fastest growing industry and growth in the pharmaceutical industry is one of the preliminary factors influencing the growth of the pharmaceutical waste management market. Various regulatory agencies such Environmental protection Agency (EPA) have set standards for pharmaceutical waste disposal, and the need to comply with such regulatory standards have fuelled the growth of the global pharmaceutical waste management market. In addition, the governments in various countries have endeavored to raise awareness and implement stringent regulations pertaining to Pharmaceutical Waste Management Market Size which have contributed to market growth. Advancements in waste disposal techniques have also spurred the growth of the market. However, such developments have increased the cost of pharmaceutical waste disposal which restricts the adoption of pharmaceutical waste management. Moreover, reluctance on the part of healthcare professionals regarding the adoption of new technologies is also likely to restrain the growth of the market in the forthcoming years. Side effects associated with pharmaceutical waste disposal methods are also possible bottlenecks to the growth of the market. The release of toxic pollutants from incineration process and scavenging in unprotected insecure landfills are hazardous and should be monitored appropriately.

Competitive Landscape

The global pharmaceutical waste management market is marked by the presence of players such as Stericycle, Covanta Holding Corporation, Stryker, US Ecology, Inc., BioMedical Waste Solution, LLC, Cardinal Health, Becton, Dickinson and Company, Daniels Health, Sharps Compliance, Inc., and Waste Management, Inc.

Segmentation

The global pharmaceutical waste management market has been segmented based on the nature of waste, type of waste, and source of waste generation.  By nature of waste, the market has been segmented into hazardous pharmaceutical waste and non-hazardous pharmaceutical waste.

By type of waste, the market has been segmented into over the counter waste, non-controlled prescription drugs, controlled drugs, and hazardous drugs.

By source of waste generation, the market has been segmented into hospitals, clinics & physicians' offices, pharmaceutical & biotechnology companies, pharmacies, and others.

Regional Analysis

North America, Europe, Asia Pacific, and the Rest of the World are the key markets for pharmaceutical waste generation. North America is one of the leading markets for pharmaceutical waste management. North America has a huge market for pharmaceutical companies and accounts for a majority of pharmaceutical sales. Presence of major pharmaceutical companies in the region also supports the growth of the market. Europe market for pharmaceutical waste management is also strong owing to the presence of a large number of biotechnology companies and community pharmacies in the region. Asia Pacific region is poised to showcase incremental growth over the forecast period. Expanding pharmaceutical industry in the region coupled with growing emphasis on pharmaceutical waste management is likely to contribute to the growth of the Asia Pacific market.

Access Report @ https://www.marketresearchfuture.com/reports/pharmaceutical-waste-management-market-6548

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Market Overview

In vitro fertilization (IVF) can be defined as a fertilization process, which generally takes place externally and involves the production of eggs, i.e., superovulation in women by injecting hormones and medication. The eggs when matured, are removed from the ovary with the help of oocyte aspiration systems and is then fertilized with the donor’s sperm, which is later grown in the laboratory until it gets developed. The final embryo is then implanted into the uterus. The global In Vitro Fertilization Market, as per a report by Market Research Future (MRFR) is touted to register a CAGR of 10.50%, surpassing a valuation of USD 12,700 million during the forecast period (2018-2023).

Get Full Report at https://www.marketresearchfuture.com/reports/in-vitro-fertilization-market-2289

Obesity is considered one of the most important factors for infertility among the population. The fat which is deposited in a women’s abdomen prevents follicular stimulation, thereby producing male hormones. Meanwhile, in males, the deposit of fats decreases the level of testosterone, which results in decreased sperm production. With the increased rate of obesity across the world, due to changing lifestyle, the in vitro fertilization market is predicted to flourish.

Factors such as the soaring prevalence of infertility due to changing lifestyle, constant efforts by the industry contributors, and initiatives by the government to offer better reimbursement policies are some of the primary growth stimulants of the IVF market. Moreover, expansion of fertility procedures to treat male infertility like ICSI will influence the market growth positively. The high availability of genomic testing with the ability to prevent the transfer of genetic disease during IVF will propel the market growth in the coming years. The rising number of IVF has influenced insurance providers to cover such procedures, which has led to competitive pricing, thereby moderating the cost of treatment. Such factors will encourage the market growth across the globe.

On the contrary, high cost of treatment, low success rates of such procedures, and ethical concerns associated to IVF are some of the major factors likely to slow down the market growth in the foreseeable future.

Global In Vitro Fertilization Market: Segmental Analysis

The In Vitro Fertilization Market has been segmented on the basis of type, product, and end users.

By type, the in vitro fertilization market is segmented into intracytoplasmic sperm injection, intrauterine insemination, and IVF using donor eggs. Of these, the intrauterine insemination segment is likely to remain attractive in the next couple of years.

By product, the market is segmented into reagent and device. Of these, the device segment is likely to outperform the reagents segment. The device segment surpassed a valuation of USD 3,700 million in 2017 and will register a healthy CAGR in the foreseeable future.

Based on the end users, the market consists of fertility clinics, clinical research institutes, and hospitals. Of these, the fertility clinics segment acquires the largest share in the global market due to the increased number of fertility centers across the globe along with the rising fertility rates globally. The hospital segment will also become profitable in the coming years due to advanced medical facilities available.

Competitive Dashboard

The top players operating in the in vitro fertilization market include Cook Medical, Cooper Surgical Fertility, Merck KGaA, Oxford Gene Technology, Thermo Fisher Scientific, INVO Bioscience, Irvine Scientific, Genea Limited, GENEA BIOMEDIX, and Vitrolife.

Regional Frontiers

Geographically, the in vitro fertilization market spans across Europe, Asia Pacific, North America, Latin America, and the Middle East & Africa.

Considering the global scenario, Europe is likely to emerge as the most attractive market for IVF. In 2017, the regional market acquired 40% of the total share, acquiring the pole position. The market’s growth can be credited to the surging funding by the government for Assisted Reproductive Technology (ART) along with the declining fertility rate among the Europeans. In this region, the UK, Germany, and France hold the major share. The region is one of the major attractions for international clients like Spain, which has the highest number of egg donors. The clinics in Europe also offer sex identification and other related IVF treatments, which further influences the market’s growth globally.

North America holds the second position due to the high availability of advance IVF technology in the region. The Asia Pacific will emerge as the fastest expanding regional market owing to rising fertility tourism, increased acceptance of the technology, and surging awareness regarding IVF among the population.

Get Full Report at https://www.marketresearchfuture.com/reports/in-vitro-fertilization-market-2289

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

New Trends/Advancements                                                                            

‘Avacen Medical,’ of late, was rewarded for developing a dry heating instrument for a kind of pain that is widely found in Fibromyalgia Drug Market. The global consulting firm, ‘Frost and Sullivan’ felicitated ‘Avacen’ with an Innovation award for making ‘Avacen 100.’ The consultant, based in Mountain View at California, designed the award post the thorough analysis of European fibromyalgia devices.

 ‘Frost and Sullivan’ presented the annual award to a firm that adopts ‘high-tech’ products for developing key products. Apart from consultation, it offers business strategies. According to one of the Frost and Sullivan analysts, this disease still remains a hindrance and the key pathology quite misunderstood.

There is a demand for substitute ‘non-invasive’ therapies to reduce pain. ‘Device-based’ treatments are essential, as a ‘placebo-regulated’ clinical examination reported that patients recorded more sleep and moderately less pain & fatigue post electro-stimulation. Avacen indulges in the sales of ‘Avacen 100’ in the U.S. for muscle-relaxation and joint-pain removal. 

Get Sample Report at https://www.marketresearchfuture.com/sample_request/1879

Fibromyalgia Treatments Market - Key Players                                   

Some of the key players in the fibromyalgia treatment market are Pfizer, GlaxoSmithKline, AstraZeneca, F. Hoffmann-La Roche AG, Astellas Pharma, Johnson & Johnson Services, Inc., SANOFI, Eli Lilly and Company, Bayer AG, ALLERGAN, Boehringer Ingelheim, AbbVie, Cephalon, Inc., Sunovion Pharms Inc, Jazz Pharmaceuticals, Vertical Pharmaceuticals, ABBOTT, NOVARTIS, and others.

Fibromyalgia Treatments Market - Segmentation

The worldwide fibromyalgia treatments market is split on account of treatments, end-users, and geographies. Treatments consist of anti-depressants, pain-relievers, therapies, anti-seizure drugs, and others. Research centers, clinics, hospitals, laboratories, etc. form the end-users. Geographically, the industry is classified on the basis of Asia Pacific, North America, Europe, and the Middle East & Africa. North America is the biggest market and followed by Europe.

Asia Pacific is projected to grow rapidly in the near future. There are lesser companies with authorized drugs, introducing prospects for several new participants. United States is the largest market, boosting North American and global sales. With North America investing in research & developments and having robust global traction, it occupies the largest shares. Regional medical expenses also contribute to its growth.

Escalating approval of novel drugs will help the fibromyalgia market grow faster across emerging & developed nations during 2016 to 2022. Few of the many eminent players in the worldwide fibromyalgia treatments market comprise Innovative Med Concepts, Eli Lilly, Forest Pharmaceuticals, Tonix Pharmaceuticals, and Theravance Biopharma. The market is hugely competitive, with multiple drugs doing the rounds on the counter. Leading firms emphasize regional expansion & drug developments to gain enhanced foothold. 

Fibromyalgia Treatments Market - Global Insights                           

The fibromyalgia treatments market is set to expand in view of increasing fibromyalgia incidences. The launch of innovative & better drugs also propels the industry. Awareness regarding fibromyalgia and reduction in misdiagnosis are likely to bode well for the market during 2016 to 2022 (forecast period). Additionally, better diagnostic criteria, resulting from constant research & developments; and high-quality & stronger treatments should boost market revenues.

Fibromyalgia symptoms include musculoskeletal pain alongside memory & sleep disorders, depression, and headaches. These may be accompanied by anxiety and irritable bowel syndrome. This disease is said to tamper with the brain’s pain sensations. A fibromyalgia patient normally experiences migraine, headaches, and TMJ (temporomandibular joint) disorders.

Fibromyalgia can increase with time. Infections, physical trauma, surgery, and psychological issues can also lead to this illness. On the other hand, the main reason behind fibromyalgia is still a mystery. The disease is found more in women than men. With no cure for fibromyalgia, some drugs; such as antidepressants, anticonvulsants, muscle-relaxants, and narcotic analgesics are used to treat it. Also, the burgeoning aged population, being more prone to fibromyalgia, raises industry sales.

Fibromyalgia is tough to detect, as many other diseases have similar indications. That is why; patients are recommended to consult their doctors, undergo the required tests, & reach a proper diagnosis. Low detection of fibromyalgia prevents the market from expanding further. Combination treatments can be harmful to patients. Thus, patients are recommended to take advice from their doctors on whether the treatments should be followed.

Fibromyalgia Treatments Market - Regional Analysis

The Americas dominates the fibromyalgia treatment market owing to the rising awareness among people, rising cases of chronic rheumatic diseases, and increasing healthcare expenditure. As per the 2017 statistics suggested by the Centers for Disease Control and Prevention (CDC), around 54.4 million adults in the United States have arthritis, which is about 25% of the population. It is also reported that by 2040, nearly 78 million adults, aged 18 years or older, are projected to have arthritis in the United States.

Europe holds the second position in the fibromyalgia treatment market. It is expected that the financial support provided by governments and private bodies for research and development and amendments in reimbursement policies in healthcare will drive the fibromyalgia treatment market in Europe.

Asia Pacific is the fastest growing market for fibromyalgia treatments, owing to a huge patient pool and rising healthcare expenditure in some countries within this region. In 2014, the total expenditure on healthcare per capita was USD 731 in China, suggested by the World Health Organization (WHO). According to the BMC Health Services Research Journal, China’s healthcare expenditure grew at a rate of 11.6% per year. The rate is much faster than the growth of the country’s economy, i.e., 9.9% per year.

The Middle East and Africa has the lowest market for fibromyalgia treatments due to lack of technical knowledge and poor medical facilities.

Browse Complete 85 Pages Premium Research Report Enabled With 66 Respective Tables And Figures at https://www.marketresearchfuture.com/reports/fibromyalgia-treatments-market-1879

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

Pages: 1 2 3 4 5 ... » »»